TipRanks
Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
Switzerland Market
SANN
Santhera Pharmaceuticals Holding
RESEARCH TOOLSreports
Want to see CH:SANN full AI Analyst Report?

Santhera Pharmaceuticals Holding (SANN) Stock Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

SANN Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Santhera
Pharmaceuticals Holding
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SANN Stock 12 Month Forecast

There Are No Analyst Ratings for CH:SANN In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

SANN Financial Forecast

SANN Earnings Forecast

The previous quarter’s earnings for SANN were -CHF1.50.
The previous quarter’s earnings for SANN were -CHF1.50.

SANN Sales Forecast

Next quarter’s sales forecast for SANN is CHF36.90M with a range of CHF36.90M to CHF36.90M. The previous quarter’s sales results were CHF48.33M. SANN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SANN has Performed in-line its overall industry.
Next quarter’s sales forecast for SANN is CHF36.90M with a range of CHF36.90M to CHF36.90M. The previous quarter’s sales results were CHF48.33M. SANN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year SANN has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:SANN
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF30
Buy
92.80%
Upside
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:SANN
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF30
Buy
92.80%
Upside
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
ASNDAscendis Pharma
AORTArtivion
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Santhera Pharmaceuticals Holding

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
4/8 ratings generated profit
50%
Average Return
+7.99%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +7.99% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
5/8 ratings generated profit
63%
Average Return
+17.84%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +17.84% per trade.
2 Years
Ram SelvarajuH.C. Wainwright
Success Rate
5/8 ratings generated profit
63%
Average Return
+9.70%
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +9.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SANN Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
3
2
2
1
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
2
2
1
0
In the current month, SANN has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SANN average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

SANN Stock Forecast FAQ

What is CH:SANN’s average 12-month price target, according to analysts?
Currently, no data Available
What is CH:SANN’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:SANN, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Santhera Pharmaceuticals Holding a Buy, Sell or Hold?
      Currently, no data Available
      What is Santhera Pharmaceuticals Holding’s share price target?
      Currently, no data Available
      What do analysts say about Santhera Pharmaceuticals Holding?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Santhera Pharmaceuticals Holding?
      To buy shares of CH:SANN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.